CERVEAU GENESIS
In 2016, Cerveau was formed to advance MK-6240 into the mainstream of neurodegenerative disease research. Since then, MK-6240 has become an acknowledged leading imaging biomarker for Tau pathologies, central to AD progression. Cerveau licensed MK-6240 from Merck and committed to establish a broad network of production facilities to support clinical research.
Through the Cerveau Users Group, Pharma companies and leading Academic centers gain access to MK-6240 for their cutting edge research, share non-competitive data with the entire Users Group and disclose breakthrough science as appropriate.
CERVEAU EVOLUTION
Dec 2016
Merck License
Feb 2017
Siemens
PETNET
Partnership
Jun 2017
MK-6240
IND Accepted
by FDA
Jul 2017
1st Dose
Supporting
Pharma Trial
Oct 2017
MK-6240
Global
Database
Opens
Dec 2017
8 Pharma
Licenses
May 2018
471 Human
Exposures
Dec 2018
25 Trials
Initiated
May 2019
1st subject in
MK-6240
ALERT
Longitudinal
Trial
Jun 2019
1575 Human
Exposures
Oct 2019
1st Subject in
Japan Phase 1
Trial
To Date
~ 5000
Human
Exposures (13
Pharma
Licenses)
CERVEAU TEAM
This dramatic growth has been enabled by the assembly of a team of highly experienced subject matter experts covering all areas essential to the production and management of MK-6240 and its associated image data.
Rick Hiatt
President & CEO
Rick Hiatt
- Global VP of Business Development for Siemens Healthcare’s Molecular Imaging Group
- President United Pharmacy Partners, a network of 50+ independent radiopharmacies
- VP of Business Logistics & Supplier Relations, Syncor International
Jack Coffey
VP Quality & Regulatory
Corporate Officer
Jack Coffey
- Previously Sr. VP of Quality & Regulatory for Cardinal Health Nuclear Pharmacy Services
- VP of Quality & Regulatory, Syncor International (now Cardinal Health)
Jamie Singer
Quality and Regulatory
Jamie Singer
- Previously Project Manager at Scientific Project Management, responsible for planning, budgeting and execution of outsourcing, quality assurance and quality control activities in support of regulatory filings
- Scientist at Pfizer Global R&D at Wyeth
Dave Casebier Ph.D.
VP Technical Operations
Corporate Officer
Dave Casebier Ph.D.
- Formerly VP of CMC forNavidea Biopharmaceuticals, working on the successful US and EU approval of Lymphoseek and the implementation of commercial supply chain and development of Flutafuranol, NAV4694
- Senior VP at Tokai Pharmaceuticals, responsible for CMC
- Senior Director at BMSMI-Lantheus Medical Imaging, program leader, discovery and development of Flurpiridaz and LMI1195
- VP at ArQule Inc, responsible for foundational technology and creation of the Production and Engineering groups
Dave Smith
Senior Planning Advisor
Dave Smith
- Current owner, CycloSmith LLC
- Radiopharmacy Consultancy and America’s representative for ORA Sprl
- Previously, Director Technical Services, IBA Molecular
- General Manager, UPPI-PET PET Operations
- Senior Support Engineer, Radiopharmacy Americas, GE Healthcare
- Clinical Engineer, Wake Forest Univ.
- Clinical Research Coordinator at The Mayo Clinic and Oregon Health and Science Univ.
Joanna Shuping
Head of Clinical Operations
Joanna Shuping
Fifteen years in drug and device clinical research including roles of increasing responsibility at:
- Cardinal Health (Sr. Consultant)
- Devicor (SME Consultant)
- Navidea (Director, Clinical Research)
- Wake Forest Health Sciences, CCC and Dept. of Neurology (Project Manager)
- The Segal Institute (Site Director) and
- Piedmont Medical Research (Clinical Research Coordinator)
Courteney Gerken
Clinical Operations
Courteney Gerken
Formerly:
- Project Manager, Ionis Pharmaceuticals
- Project Associate, Ionis Pharmaceuticals
- Executive Admin, Ionis Pharmaceuticals
-
Education:Masters in Healthcare AdministrationBachelors in Equestrian Science
Bill Abbott
VP Commercialization
Bill Abbott
- Previously in executive roles including VP Operations at Life Molecular Imaging (formally Piramal Imaging)
- President of Jubilant Draximage
- VP and General Manager of Nuclear Medicine at Bracco Diagnostics
- Upper level management positions with DuPont Pharma (now Lantheus Medical Imaging)
- Past Chair of the MITA PET Group industry forum
Stephen Arnold
CPA CFO
Stephen Arnold
- Previously, Diector, Finance CTI Molecular Imaging Inc.
- VP Finance AMETEK, Advanced Measurement Technology (NYSE: AME)
- CFO Sensus Healthcare Inc. (NASDAQ: SRTS).
- CFO ProNova Solutions
John Doumitt
Senior Planning Advisor
John Doumitt
- Previously, General Manager and CEO of HemaCare Corporation
- VP of Operations at Activus Medical Solutions
- Sr. Director of Operations Finance at Ingram Micro
- Director of Field Services at Syncor International (now Cardinal Health).
Habibi Mamone
Head of Customer Care
& Value Chain
Habibi Mamone
- Previously President and CEO of SSCM, LLC (Supply Chain Management)
- Vice President of Greenbrier (Five Star Resort)
- Director of Logistics at Siemens
Sulantha Mathotaarachchi
Solutions Architect -
Neuroinformatics
Sulantha Mathotaarachchi
- Expertise developing informatics platforms to manage and analyze healthcare data with machine learning
- 5 years of experience on software platforms and analytics in neuroimaging
- Computer Science and Engineering with Masters in Neuroscience from McGill Univ.
Thom Tulip Ph.D.
Sr. Advisor
Thom Tulip Ph.D.
- Long experience in Medical Imaging Pharmaceuticals
- Held roles of increasing responsibility at DuPont, BMS, Lantheus, Alseres, Navidea (Pres.& COO) and Fluoropharma (Pres. & CEO)
- Established and led the multidisciplinary PET group at MITA (The Medical Imaging Technology Assn.)
- Serves on the Executive Comm. of MITA’s Board of Directors
Bruno Rossi
Business Development,
Japan and Asia
Bruno Rossi
- Over twenty years of experience in the pharma in Japan and SE Asia with roles of increasing responsibility at Ciba-Geigy, Schering and Bayer in Japan, Switzerland and Singapore
- Developed the early strategy for florbetaben (amyloid PET tracer) and introduced Zevalin and Xofigo (oncology) in Japan
- Leading industry role with EFPIA in connection with the introduction of Health Technology Assessment in Japan
- Currently advising companies with a focus on business development and market access
Mas Tsuno
Special Advisor,
Mas Tsuno
- Previously Deputy Chief Clinical Officer of Neurology Clinical Development of Eisai
- Over 40 years Pharma R&D experiences based in US, Europe and Japan having held multiple management positions at Eisai including global clinical development (President, Eisai Medical Research Inc.), R&D strategy and planning, pharmacovigilance, post-marketing surveillance.
- Experiences crossing multiple therapeutic areas (neurology, immunology, oncology, gastrointestinal and cardiovascular)
Michael Reitermann
Board Member Enigma Biomedical Group
Michael Reitermann
- More than 20 years in med-tech industry
- Board member of several med-tech companies
- Former member of Managing Board of Siemens Healthineers AG
- Former head of global commercial and service operations of Siemens Healthineers AG
- Former head of diagnostics division of Siemens Healthcare
- Former head of Molecular Imaging business of Siemens Healthcare
David Morehous
General Counsel
David Morehous
- Former Senior Counsel and lead global lawyer for Siemens Healthcare’s Molecular Imaging business unit
- Former Assistant General Counsel of CTI Molecular Imaging, through $1 billion acquisition by Siemens Medical Solutions
Chase Dearborn
Senior Legal Advisor
Chase Dearborn
- Over 28 years as a lawyer in the medical devices industry
- Former General Counsel of Siemens Healthineers in Erlangen, Germany
- Former Senior Vice President, General Counsel and Secretary of the Siemens Healthcare Diagnostics Divisions in Tarrytown, NY
- Former General Counsel and Secretary of Siemens Medical Solutions USA, Inc. in Malvern, PA
Paul Graziano
Systems Administrator
Paul Graziano
- Over 25 years of experience in the Information Technology business, including business development and high-tech experience with Fortune 500 companies
- Developing innovative technology strategies, with particular expertise in Cloud computing integration and Strategic planning and development for Information Systems
SCIENTIFIC ADVISORY BOARD
The internal Cerveau team is complemented by experts from across our Users Group and by an outstanding group of renowned leaders in Neurodegenerative Disease research, clinical and non-clinical.
Professor Serge Gauthier CM, N.D., FRCPC
Director
Professor Serge Gauthier CM, N.D., FRCPC
McGill University
Alzheimer Disease and Related Disorders Research Unit, McGill Center for Studies in Aging, Douglas Research Centre and Professor, Departments of Neurology and Neurosurgery, and Psychiatry at McGill University, Quebec, Canada
Jeffrey L. Evelhoch Ph.D.,
Retired Vice-President
Jeffrey L. Evelhoch Ph.D.,
Head of Translational Biomarkers, Merck, PA
Oskar Hansson M.D., Ph.D.
Professor
Oskar Hansson M.D., Ph.D.
Clinical Memory Research, Lund University, Sweden
Richard Hargreaves Ph.D.
Senior Vice President
Richard Hargreaves Ph.D.
Currently Senior VP Head of Neuroscience TRC Research and Early Development at Myers Squibb. Previously Corporate VP, Head of Neuroscience and Imaging Research and Early Development at Celgene, VP, Head, New Indications Research Unit (NIRU) and Research & Early Development Centers of Excellence (RED-CoEs) at Biogen and VP Discovery Head for Neuroscience and VP Imaging in Merck Research Laboratories
Kenji Ishii, M.D.
Leader
Kenji Ishii, M.D.
Team for Neuroimaging Research Tokyo Metropolitan Institute of Gerontology, Japan
Keith Johnson M.D.
Director
Keith Johnson M.D.
Molecular Neuroimaging, Massachusetts General Hospital, Neurologist, Memory Disorders Unit, Brigham and Women’s Hospital, Professor of Radiology, Harvard Medical School, MA.
Eric M Reiman M.D.
Executive Director
Eric M Reiman M.D.
Banner Alzheimer’s Institute, Chief Executive Officer, Banner Research, Clinical Director of the Neurogenomics, Division at the Translational Genomics Research Institute, Professor of Psychiatry, University of Arizona and Director, Arizona Alzheimer’s Consortium, AZ
Professor Christopher Rowe FRACP M.D.., FRACP, FAANMS
Director
Professor Christopher Rowe FRACP M.D.., FRACP, FAANMS
Director of Molecular Imaging Research and a consultant neurologist to the Memory Disorders Clinic at the Austin Hospital, Australia
Koen Van Laere M.D., Ph.D., D.Sc
Head of Nuclear Medicine
Koen Van Laere M.D., Ph.D., D.Sc
Nuclear Medicine and Molecular Imaging, PET-MR Unit, Full Professor, Department of Imaging and Pathology, University Hospital Leuven-KU Leuven, Belgium